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In terms of the survival rates, the addition of iNO seems to have been more effective than the conventional ventilation treatment.
Modelling
The authors used a decision analytic model to determine the costs and effectiveness of the two treatment options. The time horizon of the model was one year, while the timeframe of the cohort study was from birth of the neonates to the end of the initial hospitalisation due to PPHN. For the purpose of the model, "death" was defined as any infant that died during the initial hospital visit for PPHN. "Survive with need for home medical support" was defined as any infant necessitating any supplemental medical support (e.g. nasogastric feeding, supplemental oxygen, medication for control of seizures). "Survive without need for home medical support" was defined as any infant that survived after hospital discharge without any supplementary medical or nursing care (except from care routinely administered). Side effects included in the analysis were divided into major and minor. Major side effects were seizures, gastrointestinal or pulmonary haemorrhage, intraventricular haemorrhage, necrotising enterocolitis, and the need to re-administer iNO after it was discontinued. Minor side effects were gastroesophageal reflux disease, infiltrated intravenous catheter necessitating therapy, or blood stream infection without cardiovascular association.
Outcomes assessed in the review
The input parameter for both treatment options used in the model was the need for ECMO rescue.
Study designs and other criteria for inclusion in the review
The authors mainly included randomised controlled trials in their review. The study population of the studies was restricted to newborns of more than 34 weeks' gestation who had hypoxic respiratory failure and evidence of pulmonary hypertension, as described in clinical or echocardiographic guidelines.
Sources searched to identify primary studies
MEDLINE and PubMed were searched for primary studies.
Criteria used to ensure the validity of primary studies
To be included, the studies had to have blinded, randomised assignment to treatment protocol without non-blinded use of iNO for rescue treatment of PPHN.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Overall, 6 primary studies were included in the review.
Methods of combining primary studies
Different results were combined into a point estimate using a Mantel-Haenszel (meta-analysis) method to estimate a combined odds ratio. The results of the meta-analysis were compared with a published meta-analysis (Finer et al. 2001, see 'Other Publications of Related Interest' below for bibliographic details).
In the sensitivity analysis, the authors extended the time horizon of the model from one year to the average lifetime of 75 years using 5% and 2% annual discount rates. 
Estimated benefits used in the economic analysis

Cost results
Conventional ventilation treatment resulted in a total cost of $40,468 per infant. The equivalent cost for iNO was $41,609.
Synthesis of costs and benefits
An incremental analysis was performed. iNO treatment resulted in an incremental cost of $19,022 per QALY gained and $33,234 per LY saved.
The one-way sensitivity analysis demonstrated that the results were robust to variability in the data. The $50,000 per QALY gained threshold was only exceeded by varying the following parameters: the total cost of the conventional ventilation group in period 1 (time from birth to the decision for ECMO therapy); the period 2 total costs (time from the decision for ECMO therapy to extubation from mechanical ventilation) in both treatment infants needing ECMO rescue treatment and who survived with major side effects; the probability of side effects with ECMO in the conventional ventilation group; and the probability of having major side effects without ECMO in the conventional ventilation group.
Varying the probability of having a major side effect without ECMO in the conventional ventilation group resulted in a threshold of greater than $100,000 per QALY gained.
When applying a 75-year time horizon, the results were improved and iNO resulted in a cost-effectiveness ratio of $976 per QALY gained. These results were robust to variations in the discount rate.
The probabilistic analyses demonstrated that iNO was cost-effective, accounting for a cut-off of $100,000 per QALY gained in 80.9% of the trials. In 35.7% of the trials iNO was found to be more cost-effective than conventional ventilation treatment, while in 3.6% of the trials it was found to be more costly and less effective than conventional treatment.
